Paul-Ehrlich-Institut

Information on the Use of Cookies

In order to operate and optimise our website, we would like to collect and analyse statistical information completely anonymously. Will you accept the temporary use of statistics cookies?

You can revoke your consent at any time in our privacy policy.

OK

Con­di­tion­al Mar­ket­ing Au­tho­ri­sa­tion Ap­pli­ca­tion sub­mit­ted for No­vavax's COVID-19 Vac­cine Nu­vax­ovid

Novavax CZ AS has submitted a conditional marketing authorisation application to the European Medicines Agency (EMA) for its COVID-19 vaccine candidate Nuvaxovid. The previous rolling review process had started for the vaccine on 03.02.2021: Since then, the successively submitted data have been continuously evaluated by the experts of the national medicinal product authorities in Europe at the EMA. The Committee for Medicinal Products for Human Use (CHMP) is expected to decide on a possible recommendation for marketing authorisation by the European Commission in a few weeks.

COVID-19 Vaccine (Source: Melinda Nagy/Shutterstock.com)

The COVID-19 vaccine Nuvaxovid (NVX-CoV2373), unlike the previously authorised vaccines against COVID-19, is neither an mRNA nor a vector vaccine: it is a protein-based vaccine and consists of virus-like particles (VLP) containing the spike protein of SARS-CoV-2. Like the other vaccines, Nuvaxovid is expected to protect against COVID-19.

Updated: 17.11.2021